GlassScriptPhysician profile
David H Shin
NPI 1831163252
$5,134.45
in general payments reported to CMS, 2019-2025
32 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906 · 2020: $90.31 · 2021: $78.91 · 2022: $1,240 · 2023: $2,174 · 2024: $218 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,736 · Education: $83.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,736.37 |
| Education | $83.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $910.15 | 2019-2024 | Trelegy Ellipta, Shingrix, Flulaval Quadrivalent |
| Novo Nordisk INC | $674.71 | 2019-2023 | Wegovy, Rybelsus, Saxenda |
| Edwards Lifesciences Corporation | $667.41 | 2021-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $494.12 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $370.08 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.64 | 2019-2023 | Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $254.24 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Novartis Pharmaceuticals Corporation | $210.89 | 2022-2023 | |
| Amgen INC. | $180.07 | 2019-2023 | Otezla, Repatha, Evenity |
| Abbvie INC. | $155.67 | 2023-2024 | Ubrelvy, Vraylar |
| Lilly USA, LLC | $126.68 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $121.97 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $81.67 | 2019-2023 | Eliquis |
| Dexcom, INC. | $58.60 | 2023-2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $53.41 | 2023-2024 | Gemtesa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $47.65 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $46.77 | 2023 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.24 | 2023 | Xifaxan, Trulance |
| Shield Therapeutics INC | $32.16 | 2023 | Accrufer |
| Daiichi Sankyo INC. | $31.30 | 2019-2022 | |
| Allergan, INC. | $29.16 | 2019 | |
| Astellas Pharma US INC | $28.06 | 2019-2023 | Veozah |
| Celltrion USA INC. | $24.38 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $20.61 | 2023 | Linzess |
| Otsuka America Pharmaceutical, INC. | $19.84 | 2024 | Rexulti |
| Resmed Corp | $19.52 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.06 | 2022 | |
| Celgene Corporation | $16.01 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.60 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $14.96 | 2023 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $14.71 | 2022 | |
| Theracosbio, LLC | $14.11 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.